Explanipedia

Subjective neuropsychological deficits in autoimmune encephalitis: Patient-informant discrepancies and cognitive test outcomes Open

Katherine Ko, Nabil Seery, Christina Kazzi, Sarah Griffith, Robb Wesselingh , et al. · 2025

Both patients and caregivers reported considerable neuropsychological impairments following AE, emphasising the ongoing burden of disease. Importantly, discrepancies between patient and informant perspectives illustrate the limitations of …

YI6 MS outcomes in breast cancer survivors and the influence of chemotherapy Open

Cassie Nesbitt, Paul G. Sanfilippo, Chao Zhu, Serkan Özakbaş, Alexandre Prat , et al. · 2025

3617 Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis Open

Nabil Seery, Paul Beech, Robb Wesselingh, Mark Schoenwaelder, James Broadley , et al. · 2025

3614 Preserving neurological function in people at high and low risk of aggressive multiple sclerosis Open

Izanne Roos, Sifat Sharmin, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina , et al. · 2025

3563 Real-world use of ofatumumab in relapsing MS: interim analysis of patient-reported and clinical outcomes from EAFToS part II Open

Anneke van der Walt, Simon Broadley, Jason Burton, Todd A. Hardy, Richard Macdonell , et al. · 2025

Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium Open

Katherine Ko, Christina Kazzi, Nabil Seery, Sarah Griffith, Robb Wesselingh , et al. · 2025

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability Open

Jessica Shipley, Heidi Beadnall, Paul G. Sanfilippo, Wei Zhen Yeh, Dana Horáková , et al. · 2025

Importance Understanding the association between pregnancy and clinical outcomes in women with moderate to severe multiple sclerosis (MS) disability is crucial for guiding family planning and management strategies. Objective To assess peri…

The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis Consortium Open

Christina Kazzi, Nabil Seery, Sarah Griffith, Robb Wesselingh, Tiffany Rushen , et al. · 2025

Background Patients with Autoimmune Encephalitis (AE) commonly report poor quality of life. There is a lack of evidence on whether clinician-rated outcome measures adequately capture patient-reported experiences. This study aimed to charac…

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024) Open

Vilija Jokubaitis, Raed Alroughani, Ayse Altıntaş, Sara Eichau, Stella Hughes , et al. · 2025

Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associa…

Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis Open

Nabil Seery, Robb Wesselingh, Paul Beech, Laurie McLaughlin, Tiffany Rushen , et al. · 2025

This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.

Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis Open

Nabil Seery, Robb Wesselingh, Paul Beech, Laurie McLaughlin, Tiffany Rushen , et al. · 2025

This study provides Class IV evidence that rituximab delays relapses in patients with anti-NMDAR antibody-mediated encephalitis.

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis Open

Simona Toscano, Tim Spelman, Serkan Özakbaş, Raed Alroughani, Clara Grazia Chisari , et al. · 2025

Persistent progression independent of relapse activity in multiple sclerosis Open

Chao Zhu, Zhen Zhou, Tomáš Kalinčík, Izanne Roos, Katherine Buzzard , et al. · 2025

Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing …

Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications Open

Julie A. Campbell, Glen J. Henson, Valery Fuh‐Ngwa, Hasnat Ahmad, Bruce Taylor , et al. · 2024

Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study Open

Krupa Pandey, Kathryn Giles, Konstantin Balashov, Richard Macdonell, Jörg Windsheimer , et al. · 2024

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies Open

Wei Zhen Yeh, Anneke van der Walt, Olga Skibina, Tomáš Kalinčík, Raed Alroughani , et al. · 2024

This study provides Class III evidence that for women with relapsing-remitting MS or clinically isolated syndrome who become pregnant, ocrelizumab, rituximab, and natalizumab (continued ≥28 weeks of gestation and restarted ≤1 month postpar…

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab Open

Anthony Honigman, Hnin P. Oo, Richard Macdonell, Johannes S. Kern · 2024

Prescription of biological disease-modifying agents for inflammatory cutaneous disease has become increasingly popular given their favourable safety profile and high rates of efficacy. Patients with multiple medical comorbidities may requi…

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome Open

Helmut Butzkueven, Anne‐Louise Ponsonby, Mark S. Stein, Robyn Lucas, Deborah Mason , et al. · 2023

Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis have been inconclusive.…

2608 COVID-19 in a single-centre cohort of patients with multiple sclerosis: no deaths and one admission Open

Ashish Pandey, James Beharry, Melanie McMurtrie, Edith Cinc, Kelli-Jane Lazarus , et al. · 2023

Objectives An understanding of the outcome of patients with multiple sclerosis (MS) who contract COVID-19 is evolving. They may be at higher risk of more severe infection as they are frequently immunosuppressed due to treatment with diseas…

2799 A longitudinal study of patients with chronic inflammatory demyelinating polyneuropathy (CIDP): identifying ultrasonographic features for prognosis Open

Nicholas Crump, Richard Macdonell · 2023

Objectives Diagnosis and treatment monitoring in CIDP is primarily based on clinical parameters. High-frequency ultrasound reflects nerve pathophysiology non-invasive and painlessly, and has been demonstrated as a useful additional diagnos…

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable Open

Sifat Sharmin, Izanne Roos, Steve Simpson, Charles B. Malpas, Marina Martínez-Sánchez , et al. · 2023

Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle and environmental factors are regarded as dri…

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis Open

Izanne Roos, Stella Hughes, Gavin McDonnell, Charles B. Malpas, Sifat Sharmin , et al. · 2023

Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS…

A Plain Language Summary On the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the Msbase Registry Open

Tim Spelman, Serkan Özakbaş, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson , et al. · 2023

The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation Open

Chao Zhu, Tomáš Kalinčík, Dana Horáková, Zhen Zhou, Katherine Buzzard , et al. · 2023

Importance Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses. Objectives To…

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis Open

Tomáš Kalinčík, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins , et al. · 2023

Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-…

Disability accrual in primary and secondary progressive multiple sclerosis Open

Sam Harding-Forrester, Izanne Roos, Ai‐Lan Nguyen, Charles B. Malpas, Ibrahima Diouf , et al. · 2023

Background Some studies comparing primary and secondary progressive multiple sclerosis (PPMS, SPMS) report similar ages at onset of the progressive phase and similar rates of subsequent disability accrual. Others report later onset and/or …

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry Open

Tim Spelman, Serkan Özakbaş, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson , et al. · 2022

Background: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience. Objectives: Use real-world data to compare…

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis Open

Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomáš Kalinčík , et al. · 2022

Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod. Methods Using data from MSBase registry, this m…

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis Open

Izanne Roos, Charles B. Malpas, Emmanuelle Leray, Romain Casey, Dana Horáková , et al. · 2022

This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.

2327 Latitude, UVR and multiple sclerosis severity Open

Marianna Vitková, Ibrahima Diouf, Charles B. Malpas, Michael Barnett, Suzanne Hodgkinson , et al. · 2022

Objectives This study aimed to investigate the association between latitude of residence, ultraviolet B radiation exposure (UVB) and MS severity. Methods This observational study used MSBase registry data. Included patients met the 2005 or…

Richard Macdonell YOU? Author Swipe